Key clinical point: Adalimumab therapy has been associated with reduced risk for morality in psoriasis patients.
Major finding: The all-cause mortality rate in psoriasis patients on long-term adalimumab was 58% lower than predicted in the general population.
Study details: ESPRIT is a prospective, observational, international, real-world registry including 6,014 psoriasis patients with a collective 28,161 person-years on adalimumab in routine clinical practice.
Disclosures: The ESPRIT registry is sponsored by AbbVie. The presenter reported serving as a consultant to and/or receiving research funding from that pharmaceutical company and nearly two dozen others.
Thaci DT. EADV Congress 2019